PRX

PRX933 hydrochloride (GW876167 hydrochloride) is an agonist of 5-HT2C receptor and can be used in studies about hypertension acute treatment.

PRX-07034 hydrochloride is a selective antagonist of 5-HT6 receptor. It has cognition and memory-enhancing properties and potently decreases food intake and body weight in rodents. PRX-07034 hydrochloride is both a potent (Ki = 4-8 nM) and highly selective 5-HT(6) receptor antagonist (≥100-fold selectivity for the 5-HT(6) receptor compared to 68 other GPCRs, ion channels, and transporters, except D(3) (Ki = 71 nM) and 5-HT(1B) (Ki = 260 nM) receptors.

PRX-08066, a selective 5-hydroxytryptamine receptor 2B (5-HT2BR, IC50= 3.4 nM) antagonist, induces selective vasodilation of pulmonary arteries.

PRX-08066 Maleic acid is the salt form of PRX-08066.PRX-08066 is a 5-HT receptor 2B antagonist with an IC50 of 3.4 nM that induces selective vasodilation of the pulmonary artery.

VRX 03011 (also known as NTC-942 and PRX-03140) is a 5-HT4 partial agonist with potential applications in the treatment of Alzheimer's disease.

Pirenoxine is an agent with anti-cataractogenesis activity by interacting with calcium ions or selenite which could lead to the formation of lens cataract.

Naluzotan(PRX 00023) is a novel and potent 5-HT1A agonist with IC50 and Ki values of approximately 20 nM and 5.1 nM, respectively.Naluzotan is a potent hERG K+ channel blocker with an IC50 value of 3800 nM.Naluzotan exhibits anxiolytic activity and can be used to study depression.

Naluzotan hydrochloride (PRX 00023 hydrochloride) is a hERG K+ channel blocker with an IC50 value of 3800 nM and is commonly used in the study of anxiety and depression.Naluzotan hydrochloride is also a novel, potent, and selective 5-HT1A agonist, with an IC50 value of about 20 nM and a Ki value of about 5.1 Naluzotan hydrochloride is also a novel, potent and selective 5-HT1A agonist with an IC50 of approximately 20 nM and a Ki of approximately 5.1 nM.

Imaprelimab (PRX-003) is a humanized IgG1 κ monoclonal antibody targeting melanoma cell adhesion molecule (MCAM), with antitumor activity and applications in studying inflammation, tumors, and psoriasis.

Tulinercept (OPRX-106), a monoclonal antibody, may be utilized in a range of biochemical research applications [1].

Topsalysin, a prostate-specific antigen (PSA)-activated protoxin, comprises a synthetic proaerolysin fusion protein targeting human prostate-specific antigen. This compound has demonstrated tumor-suppressive effects in a mouse model [1].

Bizaxofusp is a monoclonal antibody that targets the IL4R (interleukin-4 receptor).

MRGPRX1 agonist 1 is a highly potent agonist of MRGPRX1 (Mas-related G-protein-coupled receptor X1) with an EC50 of 50 nM.

(R)-MrgprX2 antagonist-3 is an antagonist of MrgprX2. It is applicable in the study of inflammatory skin diseases. For more detailed information, please refer to compound E118 in patent document WO2021092240A1.

MRGPRX2 modulator-3 (Compound 4-400) is a quinoline derivative and an MRGPRX2 regulator. It is utilized in the investigation of MRGPRX2-related conditions, including allergies, itching, pain, inflammation, and autoimmune diseases.

MrgprX2-IN-1 (Compound 2-10) is a selective antagonist of the Mas-related G protein-coupled receptor X2 (MRGPRX2). It functions by inhibiting mast cell degranulation and the release of inflammatory mediators mediated by MRGPRX2, thereby blocking non-IgE-dependent immune responses. MrgprX2-IN-1 holds potential for research into pseudo-allergic reactions, chronic pruritus, and inflammatory diseases.

MrgprX2-IN-2 (Compound example 12) is a selective antagonist of the Mas-related G protein-coupled receptor X2 (MRGPRX2). It works by inhibiting MRGPRX2-mediated mast cell degranulation and the release of inflammatory mediators, thus blocking non-IgE-dependent immune responses. MrgprX2-IN-2 shows potential for research in the areas of pseudo-allergic reactions, chronic pruritus, and inflammatory diseases.

MrgprX2 antagonist-5, which acts as a potent antagonist of MrgprX2. It exhibits the ability to effectively inhibit the activity of MrgprX2, making it an ideal candidate for research related to inflammatory skin disorders.

MrgprX2 antagonist-4 and compound B-51 E117, is a potent MrgprX2 antagonist. It specifically targets and inhibits the MrgprX2 receptor, making it suitable for investigating various inflammatory skin disorders.

MrgprX2 antagonist-1 (compound E23) is a MrgprX2 antagonist applicable to cutaneous inflammation.

MrgprX2 antagonist-3 (compound E117) is a MrgprX2 antagonist applicable for investigating cutaneous inflammation.

MrgprX2 antagonist-2 is a potent antagonist of MrgprX2. It holds potential for investigating skin inflammatory disorders.

MRGPRX1 agonist 2 (compound 1a) is a potent positive allosteric modulator of Mas-related G protein-coupled receptor X1 (MRGPRX1) with an EC50 value of 0.48 μM, and has potential for use in neuropathic pain research [1].

MRGPRX1 agonist 3 (compound 1f) is a potent positive allosteric modulator of Mas-related G protein-coupled receptor X1 (MRGPRX1) with an EC50 of 0.22 μM, and it can be used for neuropathic pain research[1].